A new study investigates how so-called “self-transcendent” psychedelic states can trigger enduring changes in meaning-making, values, and perceptions of reality.
This article was submitted by by Dr Shoona Vincent, Vice President of Clinical Science at MAC Clinical Research, as part of Psychedelic Health’s op-ed program.
In 2025, the psychedelic medicine sector reached a more defined phase of maturity, as Big Pharma entry, late-stage clinical readouts, and incremental regulatory shifts began to...
The third edition of PSYCH Symposium, held on December 4 at London’s Conway Hall, reflected a field in transition.
This article was made possible thanks to on-site reporting by Sasha Mbilika.
Psilocybin continues to gain momentum as a possible alternative to mental health treatments that leave large numbers of patients without recovery.
Compass Pathways is one of the companies spearheading clinical development of synthetic psilocybin, the compound naturally found in psilocybin mushrooms.
A new study in The Journal of Neuroscience has shed light on how the psychedelic N,N-Dimethyltryptamine, or DMT, changes brain activity during its most intense psychological...
On 4 December 2025, London’s Conway Hall will host the third PSYCH Symposium, bringing together leaders across science, policy, investment and clinical medicine to chart the...
This article was submitted by Lucy da Silva, Psychedelic Support Therapist and CEO Silva Wellness, as part of Psychedelic Health’s op-ed program.
